Multipotent Mesenchymal Stromal Cells for Pulmonary Fibrosis?

Stefanie Purdon, Carissa L. Patete, Marilyn K. Glassberg

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


With the combination of ideologic beliefs and the will to survive, fraught patients and determined clinicians seek alternative therapies for treatment of terminal conditions, such as idiopathic pulmonary fibrosis. Unfortunately, the need for treatment has supported the growth of unapproved stem cell therapy over the years spanning across many countries. The reality, however, is that the science behind this therapy is lagging. While there have been promising results from phase I trials, there remain multiple reasons that “stem cells” are not ready for clinical application, starting from a gap in understanding at the bench research level, all the way to optimal clinical application in order to provide effective therapy.

Original languageEnglish (US)
Pages (from-to)390-393
Number of pages4
JournalAmerican Journal of the Medical Sciences
Issue number5
StatePublished - May 2019
Externally publishedYes


  • Idiopathic pulmonary fibrosis
  • Stem cells
  • Therapies

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Multipotent Mesenchymal Stromal Cells for Pulmonary Fibrosis?'. Together they form a unique fingerprint.

Cite this